



## SESSION 293

# Current Management of Patients with Heart Failure (GPA)

This is intended to be a practical interactive session highlighting the current standard of care for the management of patients with proven heart failure with reduced ejection fraction. Emphasis will be placed on what classes of agents are required, and at what dose. Two recently approved new classes of medications will be reviewed, highlighting how these medications work, and how they are likely to be prescribed by specialists aiding in the care of you heart failure population.

1. To review the current standards of therapy for patients diagnosed with heart failure with reduced ejection fraction (HFrEF).
2. To highlight the potential advantages, adverse effects and costs of sacubitril/valsartan and ivabradine as additional therapies for the management of HFrEF.
3. To address specific therapeutic questions you may have in the management of HFrEF.